In the United States, out-of-pocket (OOP) costs of brand-name medications for neurological disorders increased significantly ...

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, especially for MS ...

Two decades ago, when two genetic mutations were discovered in Asia that gave scientists a better idea of how pain sensations ...

Professor Andrew Abell, Department of Chemistry and the ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Institute for Photonics and ...

The new findings show that ADCs ... contributing to chemotherapy-induced peripheral neuropathy. ADCs, a form of guided ...

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study  examined the ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

London - Abu Dhabi – Oxford Cannabinoid Technologies (“OCT” or “the Company”) is pleased to announce the successful ...

and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. - Topline results are expected in Q4 2025 and Averitas Pharma aims to submit a supplemental new drug ...

With our current indications, adults with painful diabetic peripheral neuropathy of the feet and postherpetic ... Averitas Pharma aims to submit a supplemental new drug application (sNDA) in 2026.